Heart Watch Study: a Pragmatic Randomized Controlled Trial

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

105 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-18

Study Completion Date

2024-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This will be a prospective multi-center, randomized, controlled trial of 150 patients conducted to assess the impact of individual use of the Apple Watch compared to the Withings Move on patient-reported and clinical outcomes at 6 months and up to 1 year.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Wearable Assessment of Thoracic, Cardiac Health and Exercise Performance Trial

NCT06671171

Congenital Heart Disease Pulmonary Hypertension Heart Failure +1 more

RECRUITING

Apple Heart & Movement Study

NCT04198194

Prevention

ACTIVE_NOT_RECRUITING

Detection and Quantification of Atrial Fibrillation in High-risk Patients Using a Smartwatch Wearable (Apple Watch)

NCT05686330

Atrial Fibrillation

COMPLETED NA

Utility of At-home Monitoring of Exercise Capacity by App-based 6-minute Walk Test

NCT03893500

Pulmonary Arterial Hypertension

ACTIVE_NOT_RECRUITING NA

Accuracy of Cardiac Wearables Devices to Detect Atrial Fibrillation

NCT04809922

Atrial Fibrillation (AF)

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a a randomized, controlled trial to determine the impact of the Apple Watch Series 6 compared to the Withings Move on both patient-reported outcomes and clinical utilization over 6 months and up to 1 year. Our research method will employ a patient-centered health data sharing platform (called Hugo) for real-world surveillance of outcomes in 150 total patients after they receive elective direct current cardioversion (DCCV) or catheter ablation for treatment of atrial fibrillation or atrial flutter. Patients will be enrolled at each of 3 clinical sites: Yale-New Haven Hospital, the Mayo Clinic, and Duke Health. Half of the patients will be randomized to receive the Apple Watch Series 6, while half will receive a control device (Withings Move). Patients will then be queried about specific symptoms related to atrial fibrillation and medication adherence monthly. This project will provide novel and needed post-market data about the Apple Watch Series 6 ECG and irregular rhythm detection notification features and, on a larger scale, help delineate the impact of an innovative digital health technology on real-world patient outcomes.

Specific Aim 1: To assess the impact of using the Apple Watch ECG and irregular rhythm notification features on patient-reported outcomes and clinical utilization after patients receive cardioversion or catheter ablation for atrial fibrillation or atrial flutter.

Specific Aim 2: To determine the accuracy of the Apple Watch ECG compared to physician interpretation of 12-lead ECGs obtained in routine clinical care.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardioversion Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Apple Watch

Patients will be provided with the Apple Watch Series 6 with Irregular Rhythm Detection and ECG capabilities.

Group Type EXPERIMENTAL

Apple Watch

Intervention Type DEVICE

Participants will be assigned to the Apple Watch arm to assess the impact of individual use of the Apple Watch on patient-reported and clinical utilization outcomes using Hugo.

Withings Move

Patients will be provided with the Withings Move with activity tracking.

Group Type PLACEBO_COMPARATOR

Withings Move

Intervention Type DEVICE

Participants will be assigned to the Withings Move arm to assess the impact of individual use of the Withings Move on patient-reported and clinical utilization outcomes using Hugo.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Apple Watch

Participants will be assigned to the Apple Watch arm to assess the impact of individual use of the Apple Watch on patient-reported and clinical utilization outcomes using Hugo.

Intervention Type DEVICE

Withings Move

Participants will be assigned to the Withings Move arm to assess the impact of individual use of the Withings Move on patient-reported and clinical utilization outcomes using Hugo.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>22
* English-speaking
* Planned for direct current cardioversion or catheter ablation for atrial fibrillation or atrial flutter, as noted by referring clinical staff or on chart review
* Participant is willing and able to read and sign consent and participate in study
* Participant lives independently and does not require continuous care
* Participant has an email account (or is willing to create one)
* Participant has a compatible smartphone (iPhone 6s or later)
* Participant is willing to wear only the device they are randomized to receive for the study period for as many hours during the day as they are able, except for time spent charging the device or in environments that may be suboptimal for the device
* Participant is willing to use the Hugo mobile health platform and Apple Watch Series 6 or Withings Move
* Participant has cardiology care at YNHH, Duke Health, or Mayo Clinic

Minimum Eligible Age

22 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No